The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity
Open accessAbstract
In breast cancer, genetic heterogeneity, the lack of actionable targets and immune evasion all contribute to the limited clinical response rates to immune checkpoint blockade therapy. Here, we report a high-throughput screen based on the functional interaction of mouse- or patient-derived breast tumour organoids and tumour-specific cytotoxic T cells for the identification of epigenetic inhibitors that promote antigen presentation and potentiate T-cell-mediated cytotoxicity. We show that the epigenetic inhibitors GSK-LSD1, CUDC-101 and BML-210, identified by the screen, display antitumour activities in orthotopic mammary tumours in mice, that they upregulate antigen presentation mediated by the major histocompatibility complex class I on breast tumour cells and that treatment with BML-210 substantially sensitized breast tumours to the inhibitor of the checkpoint programmed death-1. Standardized measurements of tumour-cell killing activity facilitated by tumour-organoid-T-cell screens may help with the identification of candidate immunotherapeutics for a range of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A high-throughput screening, based on the interaction between patient-derived breast cancer organoids and tumor-specific cytotoxic T cells, identified three epigenetic inhibitors - BML-210, GSK-LSD1, and CUDC-101—that displayed significant antitumor effects.44”
From Drug repurposing for cancer therapy (2024) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, Y., Liu, Y., Xu, H., Jiang, G., der Jeught, K. V., Fang, Y., Zhou, Z., Zhang, L., Frieden, M., Wang, L., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06811-z · Cited by 47
Self-citationRetractedSubramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,037
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche
Sato, T., Vries, R. G., Snippert, H. J., van de Wetering, M., Barker, N., Stange, D. E., van Es, J. H., Abo, A., Kujala, P., Peters, P. J., et al. (2009) · Nature · doi:10.1038/nature07935 · Cited by 7,204
McCarthy, D. J., Chen, Y., & Smyth, G. K. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks042 · Cited by 5,195
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684
Modeling Development and Disease with Organoids
Clevers, H. (2016) · Cell · doi:10.1016/j.cell.2016.05.082 · Cited by 3,196
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome biology · doi:10.1186/gb-2003-4-9-r60 · Cited by 2,383
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Spheroid-based drug screen: Considerations and practical approach
Friedrich, J., Seidel, C., Ebner, R., & Kunz-Schughart, L. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.226 · Cited by 1,742
Pathways of Antigen Processing
Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095910 · Cited by 1,635
Organoid modeling of the tumor immune microenvironment
Neal, J. T., Li, X., Zhu, J., Giangarra, V., Grzeskowiak, C. L., Ju, J., Liu, I. H., Chiou, S.-H., Salahudeen, A. A., Smith, A. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.11.021 · Cited by 1,556
Organoids as an in vitro model of human development and disease
Fatehullah, A., Tan, S. H., & Barker, N. (2016) · Nature Cell Biology · doi:10.1038/ncb3312 · Cited by 1,508
Human primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471
IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,418
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Yang, W., Bai, Y., Xiong, Y., Zhang, J., Chen, S., Zheng, X., Meng, X., Li, L., Wang, J., Xu, C., et al. (2016) · Nature · doi:10.1038/nature17412 · Cited by 1,010
The role of TNF superfamily members in T-cell function and diseases
Croft, M. (2009) · Nature reviews. Immunology · doi:10.1038/nri2526 · Cited by 936
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O. G., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A. L., Weiss, B. M., Finklestein, J. M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 884
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Palucka, A. K., & Coussens, L. M. (2016) · Cell · doi:10.1016/j.cell.2016.01.049 · Cited by 843
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812
Zacharakis, N., Chinnasamy, H., Black, M. A., Xu, H., Lu, Y., Zheng, Z., Pasetto, A., Langhan, M. M., Shelton, T. E., Prickett, T. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0040-8 · Cited by 786
Organoid culture systems for prostate epithelial and cancer tissue
Drost, J., Karthaus, W. R., Gao, D., Driehuis, E., Sawyers, C. L., Chen, Y., & Clevers, H. C. (2016) · Nature Protocols · doi:10.1038/nprot.2016.006 · Cited by 712
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.052 · Cited by 693
Self-citationLeone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553
Ostrand-Rosenberg, S., & Fenselau, C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701019 · Cited by 509
Tumor organoid–T-cell coculture systems
Cattaneo, C. M., Dijkstra, K. K., Fanchi, L. F., Kelderman, S., Kaing, S., van Rooij, N., van den Brink, S., Schumacher, T. N., & Voest, E. E. (2020) · Nature Protocols · doi:10.1038/s41596-019-0232-9 · Cited by 410
Crespo, M., Vilar, E., Tsai, S.-Y., Chang, K., Amin, S., Srinivasan, T., Zhang, T., Pipalia, N. H., Chen, H. J., Witherspoon, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4355 · Cited by 399
Motyka, B., Korbutt, G. S., Pinkoski, M. J., Heibein, J. A., Caputo, A., Hobman, M., Barry, M., Shostak, I., Sawchuk, T., Holmes, C. F. B., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00140-9 · Cited by 398
CD8+ T cell efficacy in vaccination and disease
Appay, V., Douek, D. C., & Price, D. A. (2008) · Nature Medicine · doi:10.1038/nm.f.1774 · Cited by 393
Munster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391
Stevanović, S., Pasetto, A., Helman, S. R., Gartner, J. J., Prickett, T. D., Howie, B., Robins, H. S., Robbins, P. F., Klebanoff, C. A., Rosenberg, S. A., et al. (2017) · Science · doi:10.1126/science.aak9510 · Cited by 378
Organoid technology and applications in cancer research
Xu, H., Lyu, X., Yi, M., Zhao, W., Song, Y., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0662-9 · Cited by 361
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 340
Self-citationClarke, S. R. M., Barnden, M., Kurts, C., Carbone, F., Miller, J. F. A. P., & Heath, W. R. (2000) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2000.00889.x · Cited by 296
Phan, N., Hong, J. J., Tofig, B., Mapua, M., Elashoff, D., Moatamed, N. A., Huang, J., Memarzadeh, S., Damoiseaux, R., & Soragni, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0305-x · Cited by 269
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Ceccacci, E., & Minucci, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.36 · Cited by 262
Qiu, G., Jin, M., Dai, J., Sun, W., Feng, J., & Jin, W. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.05.002 · Cited by 250
Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
Wu, R. C. H., Forget, M., Chacon, J. A., Bernatchez, C., Haymaker, C., Chen, J. Q., Hwu, P., & Radvanyi, L. G. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824d4465 · Cited by 249
TP53 loss creates therapeutic vulnerability in colorectal cancer
Liu, Y., Zhang, X., Han, C., Wan, G., Huang, X., Ivan, C., Jiang, D., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., Rao, P. H., et al. (2015) · Nature · doi:10.1038/nature14418 · Cited by 243
Self-citationThe Contribution of Epigenetics to Cancer Immunotherapy
Villanueva, L., Álvarez‐Errico, D., & Esteller, M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.002 · Cited by 238
Application of Cancer Organoid Model for Drug Screening and Personalized Therapy
Kondo, J., & Inoue, M. (2019) · Cells · doi:10.3390/cells8050470 · Cited by 232
Lai, C.-J., Bao, R., Tao, X., Wang, J., Atoyan, R., Qu, H., Wang, D.-G., Yin, L., Samson, M., Forrester, J. S., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3360 · Cited by 217
If we build it they will come: targeting the immune response to breast cancer
Gatti-Mays, M. E., Balko, J. M., Gameiro, S. R., Bear, H. D., Prabhakaran, S., Fukui, J. A., Disis, M. L., Nanda, R., Gulley, J. L., Kalinsky, K. M., et al. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0133-7 · Cited by 210
HDAC inhibition potentiates immunotherapy in triple negative breast cancer
Terranova-Barberio, M., Thomas, S., Ali, N., Pawlowska, N., Park, J., Krings, G., Rosenblum, M. D., Budillon, A., & Munster, P. N. (2017) · Oncotarget · doi:10.18632/oncotarget.23169 · Cited by 182
Grassi, L., Alfonsi, R., Francescangeli, F., Signore, M., Angelis, M. L. D., Addario, A., Costantini, M., Flex, E., Ciolfi, A., Pizzi, S., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1453-0 · Cited by 167
Cafri, G., Yossef, R., Pasetto, A., Deniger, D. C., Lu, Y., Parkhurst, M. R., Gartner, J. J., Jia, L., Ray, S., Ngo, L. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08304-z · Cited by 165
Dravis, C., Chung, C., Lytle, N. K., Herrera-Valdez, J., Luna, G., Trejo, C. L., Reya, T., & Wahl, G. M. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.08.001 · Cited by 139
New dimensions in tumor immunology: what does 3D culture reveal?
Feder-Mengus, C., Ghosh, S., Reschner, A., Martin, I., & Spagnoli, G. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.06.001 · Cited by 139
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Banik, D., Moufarrij, S., & Villagra, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092241 · Cited by 137
Banh, R. S., Iorio, C., Marcotte, R., Xu, Y., Cojocari, D., Rahman, A. M. A., Pawling, J., Zhang, W., Sinha, A., Rose, C. M., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3376 · Cited by 136
Checkpoint blockade in the treatment of breast cancer: current status and future directions
Wein, L., Luen, S. J., Savas, P. S., Salgado, R., & Loi, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0126-6 · Cited by 115
Gray, M. J., Gong, J., Hatch, M. M. S., Nguyen, V., Hughes, C. C. W., Hutchins, J. T., & Freimark, B. D. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0708-2 · Cited by 79
Sacchi, A., Tumino, N., Sabatini, A., Cimini, E., Casetti, R., Bordoni, V., Grassi, G., & Agrati, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01271 · Cited by 65
Inhibition of the function of class IIa HDACs by blocking their interaction with MEF2
Jayathilaka, N., Han, A., Gaffney, K. J., Dey, R., Jarusiewicz, J., Noridomi, K., Philips, M. A., Lei, X., He, J., Ye, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks189 · Cited by 59
Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?
D’Abreo, N., & Adams, S. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0216-2 · Cited by 53
ST2 as checkpoint target for colorectal cancer immunotherapy
der Jeught, K. V., Sun, Y., Fang, Y., Zhou, Z., Jiang, H., Yu, T., Yang, J., Kamocka, M. M., So, K. M., Li, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136073 · Cited by 48
Self-citationSulaiman, A., McGarry, S., Lam, K. M., El‐Sahli, S., Chambers, J., Kaczmarek, S., Li, L., Addison, C., Dimitroulakos, J., Arnaout, A., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0811-7 · Cited by 46
Self-citationHDAC inhibitors tested in phase III trial
Romero, D. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0224-2 · Cited by 43
Gogna, R., Madan, E., Kuppusamy, P., & Pati, U. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.15 · Cited by 40
Deoxyribonuclease II as a probe for chromatin structure
Hörz, W., Miller, F., Klobeck, G., & Zachau, H. G. (1980) · Journal of Molecular Biology · doi:10.1016/0022-2836(80)90094-7 · Cited by 20
Dose‐ and Dosage Form‐Dependent Pharmacokinetics of Phenacetin and its Metabolite in Man
Chiou, W. L. (1974) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1974.tb02323.x · Cited by 12
Organoids predict clinical responses
Bradley, C. A. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.25 · Cited by 7
Studying tumour-specific T cell responses in 3D
Minton, K. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0058-7 · Cited by 4
A model for tumor–immune interaction
de Souza, N. (2018) · Nature Methods · doi:10.1038/s41592-018-0165-1 · Cited by 4
Akira, K. A. W. A. (1977) · PubMed · Cited by 2
Gray, M. J., Gong, J., Nguyen, V., Hutchins, J., & Freimark, B. D. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p4-04-03 · Cited by 1
Cited by
Sorted by citations
Drug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“44 In addition, the drug atorvastatin was found to inhibit angiogenesis in a dose-dependent manner through the downregulation of vascular endothelial growth factor (VEGF), CD31, and Bcl-2 in a co-culture of glioblastoma organoids and human umbilical vein endothelial cells in fi brin gels, indicating…”
BackgroundTumor organoids: applications in cancer modeling and potentials in precision medicine
Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286
OrganoID: A versatile deep learning platform for tracking and analysis of single-organoid dynamics
Matthews, J. M., Schuster, B., Kashaf, S. S., Liu, P., Ben-Yishay, R., Ishay-Ronen, D., Izumchenko, E., Shen, L., Weber, C. R., Bielski, M. C., et al. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010584 · Cited by 179
3D cell cultures toward quantitative high-throughput drug screening
Wang, Y., & Jeon, H. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.03.014 · Cited by 143
Strategies for 3D bioprinting of spheroids: A comprehensive review
Banerjee, D., Singh, Y. P., Datta, P., Özbolat, V., O'Donnell, A., Yeo, M., & Ozbolat, I. T. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121881 · Cited by 121
Metadata
- Authors
- Zhou, Z., Van der Jeught, K., Fang, Y., Yu, T., Li, Y., Ao, Z., Liu, S., Zhang, L., Yang, Y., Eyvani, H., Cox, M. L., Wang, X., He, X., Ji, G., Schneider, B. P., Guo, F., Wan, J., Zhang, X., & Lu, X.
- Affiliations
- Indiana University Indianapolis (US)
- Indiana University Bloomington (US)
- Shanghai University of Traditional Chinese Medicine (CN)
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center (US)
- University of Maryland, College Park (US)
- Corresponding author
- Zhang, Lu
- Zhang, Xinna
- Lu, Xiongbin
- ORCID
- Venue
- Nature Biomedical Engineering
- Published
- 2021-11-01
- Volume
- 5
- Issue
- 11
- Pages
- 1320-1335
- ISSN
- 2157-846X (ISSN-L)
- PMC
- PMC8647932
- OpenAlex
- W3210520893
- Cited by
- 107
- References
- 75
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 28 · 2023: 26 · 2022: 16 · 2021: 3
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-08-30)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- Nature Biomedical Engineering (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA206366, CA243023, CA203737, CA222251)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- breast cancer, tumor organoids, epigenetic inhibitors, antigen presentation, MHC class I, T cell cytotoxicity, immune checkpoint blockade, PD-1, CUDC-101, high-throughput screening, immunotherapy, tumor immune evasion
- MeSH terms
- Animals, Breast Neoplasms, Female, Humans, Organoids, Antigen Presentation, CD8-Positive T-Lymphocytes, Epigenesis, Genetic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
